Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunshine Lake Pharma CoHKSE:06887 +1.61%15 EBITDA Margin % is 15.98% as of Dec. 2025, which is 26% below its 10-year median of 21.69. GuruFocus rates HKSE:06887 with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 957 Drug Manufacturers companies, Sunshine Lake Pharma Co ranks better than 54.34% on this metric.
Sunshine Lake Pharma Co (HKSE:06887) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sunshine Lake Pharma Co EBITDA Margin % Related Terms
Sunshine Lake Pharma Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Lake Pharma Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Lake Pharma Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Lake Pharma Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sunshine Lake Pharma Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Lake Pharma Co (HKSE:06887) has a EBITDA Margin % of 15.98% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sunshine Lake Pharma Co and its competitors. This is 26% below median its historical median of 21.69. According to the industry distribution chart, Sunshine Lake Pharma Co ranks #437 out of 957 companies in the Drug Manufacturers industry, placing it in the top 45.7%.
Is Sunshine Lake Pharma Co's EBITDA Margin % too high?
Sunshine Lake Pharma Co's current EBITDA Margin % of 15.98% is 26% below median its 10-year median of 21.69. The Drug Manufacturers industry median EBITDA Margin % is 12.14. Sunshine Lake Pharma Co's value of 15.98% is 31.6% above this industry median. Based on the distribution chart, Sunshine Lake Pharma Co ranks #437 out of 957 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sunshine Lake Pharma Co has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Sunshine Lake Pharma Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sunshine Lake Pharma Co ranks #437 out of 957 companies for EBITDA Margin %. This puts Sunshine Lake Pharma Co in the upper half of its industry. The industry median EBITDA Margin % is 12.14. Sunshine Lake Pharma Co's value of 15.98% is 31.6% above this benchmark. While the company's 10-year median is 21.69 vs. the industry median of 12.14, Sunshine Lake Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.14, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Lake Pharma Co's current EBITDA Margin % of 15.98% is 31.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sunshine Lake Pharma Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Lake Pharma Co's current EBITDA Margin % is 15.98%, which is 26% below median its own 10-year median of 21.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Lake Pharma Co stock overvalued right now?
Sunshine Lake Pharma Co (HKSE:06887) has a current EBITDA Margin % of 15.98%. The current EBITDA Margin % is 15.98%, which is 26% below median its 10-year median of 21.69 and 31.6% above the Drug Manufacturers industry median of 12.14. Sunshine Lake Pharma Co's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sunshine Lake Pharma Co (HKSE:06887), the current EBITDA Margin % is 15.98% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunshine Lake Pharma Co Ltd is a vertically integrated pharmaceutical company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. It is focused on therapeutic areas of infectious diseases, chronic diseases and oncology. The company's revenue is mainly derived from sales of pharmaceutical products to distributors in the PRC.
15GF Score
Get the complete analysis for HKSE:06887
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06887 has been successfully added to your 
